Bearish signal on weekly chart

Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
| Open | 963.05 |
| High | 974.95 |
| Low | 956.00 |
| Prev Close | 971.95 |
| Volume | 55,499 |
| VWAP(₹) | 964.27 |
| PE Ratio(x) | 38.55 |
| EPS - TTM(₹) | 25.02 |
| MCap(₹ Cr.) | 15,361.87 |
| MCap Rank | 36 |
| PB Ratio(x) | 2.18 |
| Div Yield(%) | 0.52 |
| Face Value(₹) | 1.00 |
| 52W High(₹) | 1,248.00 |
| 52W Low(₹) | 786.05 |
| MCap/Sales | 1.56 |
| Beta(1 Month) | 0.68 |
| BV/Share(₹) | 445.48 |
Dividend Announcement
Company announced a dividend of Rs 5.0 per share on May 22, 2026 with record date of Jul 24, 2026.Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 14.46% outperformed its 3 year CAGR of 9.61%. (Source: Consolidated Financials)Employee & Interest Expense
Company has spent 2.56% of its operating revenues towards interest expenses and 32.62% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)Jubilant Life Share Price Update
Jubilant Pharmova Ltd. share price moved down by -0.78% from its previous close of Rs 971.95. Jubilant Pharmova Ltd. stock last traded price is 964.45
| Share Price | Value |
|---|---|
| Today/Current/Last | 964.45 |
| Previous Day | 971.95 |
Found Insights useful?
| 1 Day | -0.78% |
| 1 Month | -4.34% |
| 3 Months | 18.72% |
| 1 Year | -15.86% |
| 3 Years | 168.42% |
| 5 Years | 23.81% |
4 Analysts
| Ratings | Current | 1W Ago | 1M Ago | 3M Ago |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 |
| Hold | - | - | - | - |
| Sell | - | - | - | - |
| Strong Sell | - | - | - | - |
| # Analysts | 4 | 4 | 4 | 4 |
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Income | 2,143.00 | 1,976.20 | 1,912.70 | 1,940.70 | 1,830.90 |
| Total Income Growth (%) | 8.44 | 3.32 | -1.44 | 6.00 | 3.21 |
| Total Expenses | 1,993.40 | 1,735.60 | 1,709.20 | 1,681.90 | 1,644.50 |
| Total Expenses Growth (%) | 14.85 | 1.54 | 1.62 | 2.27 | 4.85 |
| EBIT | 149.60 | 240.60 | 203.50 | 258.80 | 186.40 |
| EBIT Growth (%) | -37.82 | 18.23 | -21.37 | 38.84 | -9.29 |
| Profit after Tax (PAT) | 55.90 | 120.30 | 102.90 | 153.60 | 100.90 |
| PAT Growth (%) | -53.53 | 16.91 | -33.01 | 52.23 | -1.85 |
| EBIT Margin (%) | 6.98 | 12.17 | 10.64 | 13.34 | 10.18 |
| Net Profit Margin (%) | 2.61 | 6.09 | 5.38 | 7.91 | 5.51 |
| Basic EPS (₹) | 3.52 | 7.59 | 6.49 | 9.71 | 6.37 |
All figures in Rs Cr, unless mentioned otherwise
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 14.46% outperformed its 3 year CAGR of 9.61%. (Source: Consolidated Financials)Employee & Interest Expense
Company has spent 2.56% of its operating revenues towards interest expenses and 32.62% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)| Annual | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Assets | 12,756.40 | 11,548.50 | 11,156.65 | 9,990.87 | 8,918.11 |
| Total Assets Growth (%) | 10.46 | 3.51 | 11.67 | 12.03 | -28.78 |
| Total Liabilities | 6,517.80 | 6,127.40 | 5,764.86 | 4,674.47 | 4,176.59 |
| Total Liabilities Growth (%) | 6.37 | 6.29 | 23.33 | 11.92 | -39.63 |
| Total Equity | 6,238.60 | 5,421.10 | 5,391.79 | 5,316.40 | 4,741.52 |
| Total Equity Growth (%) | 15.08 | 0.54 | 1.42 | 12.12 | -15.39 |
| Current Ratio (x) | 1.65 | 2.05 | 2.12 | 2.20 | 2.82 |
| Total Debt to Equity (x) | 0.39 | 0.63 | 0.63 | 0.55 | 0.54 |
| Contingent Liabilities | 1,214.10 | 1,360.40 | 1,256.59 | 842.82 | 887.12 |
All figures in Rs Cr, unless mentioned otherwise
| Annual | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash flow from Operating Activities | 1,072.10 | 971.30 | 660.67 | 837.54 | 1,784.27 |
| Net Cash used in Investing Activities | 487.70 | -607.90 | -544.41 | -380.37 | -739.01 |
| Net Cash flow from Financing Activities | -1,452.70 | -432.50 | -156.68 | -32.60 | -1,709.39 |
| Net Cash Flow | 131.90 | -57.50 | 30.10 | 481.86 | -728.86 |
| Closing Cash & Cash Equivalent | 1,088.30 | 956.40 | 1,013.92 | 983.82 | 501.96 |
| Closing Cash & Cash Equivalent Growth (%) | 13.79 | -5.67 | 3.06 | 96.00 | -59.22 |
| Total Debt/ CFO (x) | 2.27 | 3.51 | 5.16 | 3.50 | 1.45 |
All figures in Rs Cr, unless mentioned otherwise
| Annual | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Return on Equity (%) | 13.41 | 1.41 | -1.12 | 7.78 | 17.62 |
| Return on Capital Employed (%) | 8.13 | 6.08 | 2.77 | 9.35 | 13.53 |
| Return on Assets (%) | 6.58 | 0.66 | -0.54 | 4.14 | 9.37 |
| Interest Coverage Ratio (x) | 5.12 | 3.56 | 4.33 | 8.03 | 5.79 |
| Asset Turnover Ratio (x) | 0.60 | 0.59 | 0.59 | 0.02 | 68.38 |
| Price to Earnings (x) | 16.81 | 117.65 | -72.99 | 14.93 | 12.97 |
| Price to Book (x) | 2.25 | 1.65 | 0.82 | 1.16 | 2.28 |
| EV/EBITDA (x) | 12.54 | 11.79 | 8.38 | 6.95 | 9.01 |
| EBITDA Margin (%) | 17.00 | 14.46 | 12.96 | 19.04 | 23.18 |
Found Financials useful?
Stochastic Crossover
Bearish signal on weekly chart
Appeared on: 5 Jun 2026
Region: Overbought (Above 80)
Average price decline of -7.00% within 7 weeks of Bearish signal in last 10 years
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
| R1 | 973.13 | Pivot 966.57 | S1 | 958.18 |
| R2 | 981.52 | S2 | 951.62 | |
| R3 | 996.47 | S3 | 936.67 |
| 5 Days | 14 Days | 28 Days |
| 23.02 | 26.48 | 28.47 |
Found Technicals useful?
Choose from Peers
Choose from Stocks
Found Peer Comparison useful?
MF Ownership as on 30 April 2026
303.85
Amount Invested (in Cr.)
1.2%
% of AUM
29.26
% Change (MoM basis)
273.09
Amount Invested (in Cr.)
0.899088%
% of AUM
0.00
% Change (MoM basis)
173.64
Amount Invested (in Cr.)
0.67%
% of AUM
0.00
% Change (MoM basis)
Board Meeting
Quarterly Results
Jan 22, 2026
Board Meeting
Quarterly Results
Oct 14, 2025
General Meeting
-
Aug 06, 2025
| Announced on | Meeting on |
| Jan 22, 2026 | Feb 06, 2026 |
| Quarterly Results | |
| Oct 14, 2025 | Oct 31, 2025 |
| Quarterly Results | |
| Jul 23, 2025 | Jul 29, 2025 |
| Quarterly Results | |
| Apr 30, 2025 | May 16, 2025 |
| Audited Results & Final Dividend | |
| Jan 23, 2025 | Jan 31, 2025 |
| Quarterly Results | |
| Announced on | Ex-Date | Dividend% |
| May 16, 2025 | Jul 25, 2025 | 500% |
| May 29, 2024 | Aug 02, 2024 | 500% |
| May 29, 2023 | Aug 10, 2023 | 500% |
| May 27, 2022 | Aug 11, 2022 | 500% |
| Jun 04, 2021 | Aug 05, 2021 | 500% |
| Announced on | Ex-Date |
| Feb 03, 2004 | Mar 12, 2004 |
| Bonus Ratio: 3 share(s) for every 5 shares held | |
| Announced on | Ex-Date |
| Jan 14, 2006 | Mar 17, 2006 |
| Split: Old FV5.0| New FV:1.0 | |
| Jul 18, 2002 | Nov 12, 2002 |
| Split: Old FV10.0| New FV:5.0 | |
No Data Available
| Announced on | Meeting on |
| Aug 06, 2025 | Aug 29, 2025 |
| - | |
| Jun 25, 2025 | Jul 26, 2025 |
| - | |
| Aug 12, 2024 | Aug 30, 2024 |
| - | |
| Jul 30, 2024 | Aug 25, 2024 |
| - | |
| May 28, 2024 | Jun 28, 2024 |
| - | |
Jubilant Pharmova Ltd., incorporated in the year 1978, is a Mid Cap company (having a market cap of Rs 15,361.87 Crore) operating in Pharmaceuticals sector.
Industry
Key Indices Listed On
Nifty 500, BSE 500, BSE 250 SmallCap Index, BSE SmallCap, BSE Healthcare
Address
Bhartiagram,Gajraula,Amroha District, Uttar Pradesh - 244223
Hari S Bhartia
Co-ChairmanShyam S Bhartia
ChairmanPriyavrat Bhartia
Managing DirectorArjun Shanker Bhartia
Joint Managing DirectorDATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.